Ibrutinib
- PDF / 169,293 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 47 Downloads / 160 Views
1
S
Cheek haematoma: case report An 87-year-old man developed cheek haematoma during treatment with ibrutinib for chronic lymphoid leukaemia. The man, who had chronic lymphoid leukaemia, started receiving ibrutinib [dosage and route not stated]. Subsequently, he underwent a routine excision of a cutaneous malignancy affecting the cheek. However, he developed cheek haematoma postoperatively, which was suspected to be related to ibrutinib [duration of treatment to reaction onset not stated]. The man then returned to the operation theater, and required to undergo evacuation and haemostasis of the haematoma. Author comment: "Ibrutinib represents a novel bleeding risk factor and its perioperative use must be considered with caution." Gijn DV, et al. Ibrutinib - a novel risk factor in postoperative bleeding and haematoma formation. British Journal of Oral and Maxillofacial Surgery 57: e35 abstr. P91, No. 10, Dec 2019. Available from: URL: http://doi.org/10.1016/ 803444069 j.bjoms.2019.10.095 [abstract] - United Kingdom
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
